Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

1 Apr 2025

Abstract excerpt

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy depends on T cells that are genetically modified to recognize and attack cancer cells. Their effectiveness thus hinges on the functionality of a patient's own T cells. Since CAR T-cell therapy is currently only approved for advanced cancers after at least one line of chemotherapy, we evaluated the potential negative effects of prior exposure to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Single-cell and spatial transcriptomics
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40210237
DOI: 10.1136/jitc-2024-010709

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphomaPMID 40210237Read ↗

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancySemantic proximity Read ↗

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic ReprogrammingSemantic proximity Read ↗

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read ↗

Harnessing the Transcriptional Signatures of Car-T Cells and Leukemia/Lymphoma Using Single-Cell Sequencing TechnologiesSemantic proximity Read ↗

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaSemantic proximity Read ↗

Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell TherapySemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.Semantic proximity Read ↗

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansionSemantic proximity Read ↗

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read ↗

Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.